Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

Other research analysts also recently issued research reports about the company. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 8th. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Evercore lifted their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Finally, Scotiabank raised their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $788.57.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $785.51 on Friday. The company’s fifty day moving average price is $757.29 and its 200-day moving average price is $658.22. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 4.22. The firm has a market capitalization of $82.56 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 2.11 and a beta of 0.40. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the firm posted $12.07 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.02% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Dodge & Cox grew its stake in shares of Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $628,151,000. AQR Capital Management LLC grew its position in Regeneron Pharmaceuticals by 528.7% during the third quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock valued at $405,596,000 after buying an additional 606,612 shares during the period. Invesco Ltd. increased its holdings in Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after buying an additional 408,649 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after acquiring an additional 326,583 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.